NASDAQ:LIVN - GB00BYMT0J19 - Common Stock
The current stock price of LIVN is 56.37 USD. In the past month the price increased by 37.05%. In the past year, price increased by 11.87%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.07 | 230.89B | ||
ISRG | INTUITIVE SURGICAL INC | 58.79 | 169.67B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.28 | 156.32B | ||
SYK | STRYKER CORP | 30.46 | 149.64B | ||
MDT | MEDTRONIC PLC | 16.78 | 119.05B | ||
BDX | BECTON DICKINSON AND CO | 13.52 | 55.31B | ||
IDXX | IDEXX LABORATORIES INC | 53.88 | 51.77B | ||
EW | EDWARDS LIFESCIENCES CORP | 31.65 | 47.75B | ||
RMD | RESMED INC | 28.74 | 40.19B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.82 | 33.66B | ||
DXCM | DEXCOM INC | 44.32 | 29.55B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 16.42 | 26.56B |
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
LIVANOVA PLC
20 Eastbourne Terrace
London W2 6LG GB
CEO: Damien McDonald
Employees: 2900
Phone: 442033250662
The current stock price of LIVN is 56.37 USD. The price increased by 1.66% in the last trading session.
The exchange symbol of LIVANOVA PLC is LIVN and it is listed on the Nasdaq exchange.
LIVN stock is listed on the Nasdaq exchange.
16 analysts have analysed LIVN and the average price target is 64.9 USD. This implies a price increase of 15.14% is expected in the next year compared to the current price of 56.37. Check the LIVANOVA PLC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
LIVANOVA PLC (LIVN) has a market capitalization of 3.08B USD. This makes LIVN a Mid Cap stock.
LIVANOVA PLC (LIVN) currently has 2900 employees.
LIVANOVA PLC (LIVN) has a support level at 52.85 and a resistance level at 56.38. Check the full technical report for a detailed analysis of LIVN support and resistance levels.
The Revenue of LIVANOVA PLC (LIVN) is expected to grow by 9.76% in the next year. Check the estimates tab for more information on the LIVN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LIVN does not pay a dividend.
LIVANOVA PLC (LIVN) will report earnings on 2025-10-28, before the market open.
The PE ratio for LIVANOVA PLC (LIVN) is 15.49. This is based on the reported non-GAAP earnings per share of 3.64 and the current share price of 56.37 USD. Check the full fundamental report for a full analysis of the valuation metrics for LIVN.
The outstanding short interest for LIVANOVA PLC (LIVN) is 4.19% of its float. Check the ownership tab for more information on the LIVN short interest.
ChartMill assigns a technical rating of 9 / 10 to LIVN. When comparing the yearly performance of all stocks, LIVN is one of the better performing stocks in the market, outperforming 80.99% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to LIVN. LIVN has only an average score on both its financial health and profitability.
Over the last trailing twelve months LIVN reported a non-GAAP Earnings per Share(EPS) of 3.64. The EPS increased by 11.66% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -8.43% | ||
ROE | -18.82% | ||
Debt/Equity | 0.31 |
16 analysts have analysed LIVN and the average price target is 64.9 USD. This implies a price increase of 15.14% is expected in the next year compared to the current price of 56.37.
For the next year, analysts expect an EPS growth of 13.43% and a revenue growth 9.76% for LIVN